TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33581097
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for PH, primarily phosphodiesterase‐5 inhibitors
Study: 33581097
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for PH
Study: 33581097
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for PH in severe PH‐COPD
Study: 33209019
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (10 g, two times per day for 14 days)
Study: 35445748
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine (0.03 mg/kg)
Study: 35445748
Drug: Intranasal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buprenorphine (0.03 mg/kg)
Study: 35445748
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal buprenorphine (0.03 mg/kg)
Study: 33806529
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg every night for six weeks
Study: 35472193
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (32 international units)
Study: 35472193
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin
Study: 32553118
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus berzosertib (210 mg/m2 on day 2 and day 9 of a 21-day cycle)
Study: 32553118
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1000 mg/m2 on day 1 and day 8 of a 21-day cycle)
Study: 35076933
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) with delayed PSA screening at age 50
Study: 32050792
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy combined with psychological intervention (Cognitive behavioral therapy)
Study: 32050792
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy only (Control group)
Study: 34294416
Drug: DCVAC/OvCa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVAC/OvCa plus chemotherapy (carboplatin and gemcitabine)
Study: 35880079
Drug: S.boulardii monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S.boulardii monotherapy for 2 weeks followed by bismuth quadruple therapy if H. pylori positive after 4 weeks
Study: 35880079
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 6 weeks followed by bismuth quadruple therapy if H. pylori positive
Study: 35880079
Drug: Total treatment
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total treatment effect of S.boulardii and bismuth quadruple therapy
Study: 32593555
Drug: Brief oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief oral information and a leaflet on advanced directives (AD) provided by General Practitioners (GPs)
Study: 35402445
Drug: CSF‐aspiration group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF‐aspiration group (Group A) received spinal anesthesia with 10 mg of hyperbaric 0.5% bupivacaine with aspiration of 0.2 ml of CSF.
Study: 35402445
Drug: No‐CSF‐aspiration group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐CSF‐aspiration group (Group B) received only 10 mg of 0.5% hyperbaric bupivacaine.
Study: 32390454
Drug: non-efavirenz regimens
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-efavirenz regimens or no antiretroviral therapy
Study: 34495173
Drug: Stratification by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratification by Degree of Clinical Severity and Abandonment Risk of Tuberculosis Treatment (SRTB)
Study: 35842610
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg) combined with 30 mL of 0.33% ropivacaine
Study: 35842610
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg) combined with 20 mL of 0.5% ropivacaine
Study: 32622816
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) followed by Thought Field Therapy (TFT)
Study: 32144833
Drug: Resveratrol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 1,000 mg per day for 8 weeks
Study: 33607312
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg administered intravenously on day 1 of a 42-day cycle for two cycles.
Study: 33607312
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 administered intravenously on days 1 to 5 of a 21-day cycle.
Study: 33930787
Drug: RDA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA diet (0.8 g/kg body weight/d)
Study: 33930787
Drug: 2RDA diet
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA diet (2.0 g/kg body weight/d)
Study: 34769863
Drug: Oral function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral function training program
Study: 32729919
Drug: Algorithm for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm for determining medication count
Study: 33529783
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) tranexamic acid (TXA) - two 1-g boluses, one prior to tourniquet inflation and one prior to wound closure
Study: 33529783
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) tranexamic acid (TXA)
Study: 34578863
Drug: Vitamin D3-enriched
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-enriched Gouda-type cheese (5.7 μg of vitamin D3)
Study: 35921235
Drug: FIL 200
Normalized name: avanafil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL 200 mg plus MTX
Study: 35921235
Drug: FIL 100
Normalized name: avanafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL 100 mg plus MTX
Study: 35921235
Drug: FIL 200
Normalized name: avanafil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL 200 mg
Study: 33855215
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (< 100 g carbohydrates/day)
Study: 33855215
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (> 250 g carbohydrates/day)
Study: 32623701
Drug: Anti-IBS syrup
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IBS syrup (15 mL, thrice daily for 6 weeks)
Study: 32623701
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (similar preparation without plant extract)
Study: 35723849
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg by slow intravenous infusion for three days
Study: 35723849
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (national therapy only)
Study: 34383325
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with a 980-nm diode laser set at 6.89 W/cm2 energy density, 0.5 W power, and a tip diameter of 10 mm for 15 seconds.
Study: 33073737
Drug: Ad26.ZEBOV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV and MVA-BN-Filo two-dose vaccination regimens
Study: 38552629
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 4 g/day
Study: 34578807
Drug: Soy protein-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein-based supplement
Study: 35012310
Drug: PS-enriched beverage
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-enriched beverage (2 g PS/day)
Study: 36114662
Drug: Brachial artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachial artery responses during hypercapnia without α₁‐adrenergic receptor blockade (prazosin; 0.05 mg/kg)
Study: 36114662
Drug: Brachial artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachial artery responses during hypercapnia with α₁‐adrenergic receptor blockade (prazosin; 0.05 mg/kg)
Study: 33973307
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (nivolumab 1 mg/kg i.v. plus ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles, followed by nivolumab 240 mg i.v. every 2 weeks)
Study: 34590926
Drug: Kyusho Jitsu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kyusho Jitsu intervention (twice a week for 6 months)
Study: 35509219
Drug: Oral ARD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ARD-101 (40, 100, and 240 mg)
Study: 35509219
Drug: Oral ARD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ARD-101 (240 mg)
Study: 34479739
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell therapy
Study: 34487151
Drug: Pradefovir 30
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 30 mg
Study: 34487151
Drug: Pradefovir 60
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 60 mg
Study: 35237340
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium dispersible tablets
Study: 32935954
Drug: Motor program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor program activating therapy (MPAT), 1 hour, twice a week for two months.
Study: 32935954
Drug: Vojta reflex
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vojta reflex locomotion (VRL), 1 hour, twice a week for two months.
Study: 35081280
Drug: Tofacitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (10 mg twice daily)
Study: 34370282
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGA)
Study: 33620516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a diagnostic RA code with biologic infusion codes
Study: 32901996
Drug: 15°C PCM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15°C PCM treatment covering the quadriceps for three hours
Study: 36048114
Drug: Low dose/preferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose/preferred flavor
Study: 35193609
Drug: Bovine milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk-based formula containing L. reuteri DSM 17938 at 1 × 10^7 CFU/g (Control Group; CG)
Study: 35193609
Drug: Bovine milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk-based formula with added 1.0 g/L 2'FL (Experimental Group; EG)
Study: 36468967
Drug: 1.4% silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% silymarin cream
Study: 32233208
Drug: Compound Amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Amino Acid Capsules (CAAC) combined with clomiphene for 12 weeks
Study: 33567135
Drug: Subcuticular suturing
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcuticular suturing and early scar management with non‐ablative fractional laser (NAFL) and intralesional triamcinolone injection (ILI)
Study: 37403410
Drug: L-lactate
Normalized name: L-lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lactate
Study: 32164719
Drug: Compensatory acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensatory acupuncture therapy (Control)
Study: 34989824
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (AOM) at 400 mg
Study: 34989824
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole at 10-20 mg
Study: 39316284
Drug: CTC 200
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC 200 mg BID
Study: 35974668
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg QID
Study: 35174869
Drug: Intensive circuit
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive circuit class therapy
Study: 37648382
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy
Study: 32403113
Drug: Third-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line therapy
Study: 33783006
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with pan-genotypic DAA (sofosbuvir and velpatasvir with or without ribavirin)
Study: 34741341
Drug: Dietary mulberry-leaf
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary mulberry-leaf flavonoids (MF) 30 mg/kg
Study: 34741341
Drug: Dietary mulberry-leaf
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary mulberry-leaf flavonoids (MF) 60 mg/kg
Study: 36401233
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonide (IVTA) combined with standard phacoemulsification surgery
Study: 33444116
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (5 mg/kg) every 2 weeks (CPB arm)
Study: 33444116
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) without Bevacizumab (CP arm)
Study: 36473191
Drug: Topical Cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyclosporin A 0.1% (CsA), once daily for 12 weeks
Study: 36473191
Drug: Topical Diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Diquafosol Tetrasodium 3% (DQS), six times a day for 12 weeks
Study: 36473191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CsA and DQS, for 12 weeks
Study: 32919916
Drug: Sacubitril/valsartan therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan therapy
Study: 35157791
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg 3 times daily
Study: 35157791
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg 3 times daily
Study: 33208340
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A)
Study: 33452004
Drug: FIL200 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL200 monotherapy
Study: 34327739
Drug: GSK3335065 (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3335065 (1.3 mg)
Study: 32453369
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally twice daily for 2 years (n=133)
Study: 36438801
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of vancomycin every 12 h
Study: 36438801
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of vancomycin every 8 h
Study: 33188423
Drug: Refined rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined rice bran, flaxseed, and sesame seed oils (30 g per day for 8 weeks)
Study: 33963734
Drug: Ready-to-use therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use therapeutic food (RUTF) and amoxicillin along with standard nutrition counseling for 2-12 weeks
Study: 33361021
Drug: MAO‐B inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAO‐B inhibitor (Selegiline 5 mg)
Study: 33361021
Drug: Donepezil (DNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (DNP 10 mg daily)
Study: 33755218
Drug: Chlorhexidine oral
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine oral rinse
Study: 36435988
Drug: CII elastics
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CII elastics (100-150 g/side), full time
Study: 33556410
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + saffron supplement (150 mg after each session)
Study: 33556410
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + placebo (dextrose pill)
Study: 33556410
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + saffron supplement
Study: 36286887
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment (Zacofalk) in subgroup Ia (n=58)
Study: 32340903
Drug: 16 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/d native inulin
Study: 34436555
Drug: Web-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based diet and lifestyle intervention utilizing short animated videos, delivered weekly for 5 weeks.
Study: 35114186
Drug: 125 cc/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 cc/h normal saline
Study: 35114186
Drug: 250 cc/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 cc/h normal saline
Study: 33608403
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of insulin
Study: 36499011
Drug: Rhubarb extract
Normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb extract (RE) 12.5 mg per day
Study: 36499011
Drug: Rhubarb extract
Normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb extract (RE) 25 mg per day
Study: 33963015
Drug: Adjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant ipilimumab 3 mg/kg (ipi3)
Study: 33963015
Drug: Adjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant ipilimumab 10 mg/kg (ipi10)
Study: 35249863
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticancer drugs
Study: 32805594
Drug: Manual milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual milk administration by parents (MAP)
Study: 32805594
Drug: Electric syringe
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric syringe administration (ESA)
Study: 33400237
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) group, n = 11; dose 40 × 10^6 Treg cells/kg of body weight
Study: 33400237
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal (IT) group, n = 3; dose 1.0 × 10^6 Treg cells
Study: 32404132
Drug: Robotic rehabilitation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic rehabilitation using Tymo system or Walker View in addition to traditional therapy
Study: 35017258
Drug: Analgesic (ANA)
Normalized name: ANALGESIC CREAM
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (ANA) treatment (metamizole/dipyrone) with observational learning (positive video)
Study: 35017258
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment with observational learning (positive video)
Study: 35017258
Drug: Analgesic (ANA)
Normalized name: ANALGESIC CREAM
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (ANA) treatment (metamizole/dipyrone) with neutral video
Study: 35017258
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment with neutral video
Study: 35017258
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication or observational learning)
Study: 32005277
Drug: Adaptive Servo-Ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive Servo-Ventilation (ASV) therapy added to PCI and optimal medical management
Study: 32005277
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy and PCI alone (control)
Study: 32130122
Drug: eHealth tool
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth tool with electronic survey and tailored resources for physical activity (PA) prescription
Study: 33754642
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg)
Study: 32348101
Drug: Diosmin 600
Normalized name: diosmin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin 600 mg once daily for 12 months